Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, has announced that Iraj Ali, CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 8:15 a.m. ET. This event will showcase their innovative work in precision T cell therapies aimed at treating solid tumors, specifically focusing on clonal neoantigens unique to each patient. A live and archived webcast of the presentation will be accessible via the Events & Presentations section on the Achilles website.

LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.

A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.

About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with unresectable locally advanced and metastatic non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Further information:

Lee M. Stern – VP, IR & External Communications
+1 (332) 373-2634
l.stern@achillestx.com

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com

FAQ

When will the ACHL presentation at the J.P. Morgan Healthcare Conference take place?

The ACHL presentation is scheduled for January 13, 2022, at 8:15 a.m. ET.

What is the focus of Achilles Therapeutics' presentation at the conference?

The focus will be on their precision T cell therapies for treating solid tumors.

Where can I watch the ACHL presentation from the J.P. Morgan Healthcare Conference?

The presentation will be available live and archived on the Events & Presentations section of the Achilles website.

What clinical trials is ACHL currently involved in?

ACHL is conducting Phase I/IIa trials, including the CHIRON trial for non-small cell lung cancer and the THETIS trial for melanoma.

What technology does ACHL use to develop its T cell therapies?

ACHL utilizes DNA sequencing data and its PELEUS™ bioinformatics platform to identify patient-specific clonal neoantigens.